Altimmune Inc ALT

$2.67 -0.06 (-2.38%)

Valuation

Market cap
532,007,000
Revenue TTM
$40,000
Net income TTM
$-88,090,000
PE ratio
0.00
Forward PE
—
Profit margin
-220,225.00%
Debt to equity
0.12

Trading

Volume
3,839,200
Avg volume
4,519,648
Day's range
$2.65 – $2.75
Shares out
194,518,000
Stochastic %K
3%
Beta
0.06
Analysts
Strong Sell
Price target
$14.54

Price

Company profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is...

Show more

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
240 654 1450
Website
https://altimmune.com
Address
910 Clopper Road, Suite 201S, Gaithersburg, United States

Latest news

Stocktwits

Aaodania Oct 6, 2:33 AM
$ALT 2.6 is the button. I will go in tomorrow.
0 replies
Cs1000lb Oct 6, 2:29 AM
$ALT worst financial decision I’ve ever made. I hate this stock so much. See you tomorrow
0 replies
Turribull Oct 6, 2:20 AM
$ALT Monday Night Musing. 89Bio hit their 52wk low 5 months before their buyout. Altimmune hit their 52wk low 5 months ago. Take that any way you’d like. 😉
0 replies
Wolly99 Oct 6, 12:12 AM
$ALT GSK looking for a market lead for their “MASH/ALD Franchise” https://jobs.gsk.com/gb/en/job/448333/Sr-Director-MASH-ALD-Brand-Lead-Pipeline It’s based around efimosfermin, which just started a p2 in ALD. But I don’t know what they plan to do for AUD/curbing alcohol abuse. Healing the liver with an FGF12 is one thing, but you also want to stop the assault on hepatocytes via alcohol use. Still seems like they need a GLP to make a true liver franchise.
1 replies
TunA305 Oct 5, 11:53 PM
$ALT chat gpt alert
1 replies
TunA305 Oct 5, 11:52 PM
$ALT chat gpt alert
0 replies
AchieveNonDillutiveFunds Oct 5, 11:45 PM
$ALT
0 replies
Corpkcots Oct 5, 11:12 PM
$ALT Wow, 74% dark pool short volume today! They are really working it over! Go ALT
2 replies